Orantinib

Drug Profile

Orantinib

Alternative Names: SU 006668; SU 6668; TSU-68

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Pfizer
  • Developer Pfizer; Taiho Pharmaceutical
  • Class Antineoplastics; Indoles; Propionic acids; Pyrroles; Small molecules
  • Mechanism of Action Fibroblast growth factor inhibitors; Platelet-derived growth factor inhibitors; Protein tyrosine kinase inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Colorectal cancer; Gastric cancer; Hepatocellular carcinoma; Non-small cell lung cancer
  • Discontinued Solid tumours

Most Recent Events

  • 31 Jul 2014 Taiho Pharmaceutical terminates the phase III ORIENTAL trial for Hepatocellular carcinoma (unresectable disease; combination therapy) in Japan, South Korea & Taiwan (NCT01465464)
  • 18 Feb 2014 Taiho Pharmaceutical completes enrolment in the phase III ORIENTAL trial for Hepatocellular carcinoma (unresectable disease; combination therapy) in Japan, South Korea & Taiwan (NCT01465464)
  • 13 Apr 2012 Orantinib is still in phase I trials for Non-small cell lung cancer in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top